Press release
SINOVAC Announces Appointment of Independent Auditor
Critical step in improving transparency and resuming trading on NASDAQ BEIJING--(BUSINESS WIRE)-- The Board of Directors and Management of SINOVAC Biotech
About this update from Sinovac Biotech, Ltd.
[{"type":"text","content":"\nCritical step in improving transparency and resuming trading on NASDAQ\n\n\n BEIJING--(BUSINESS WIRE)--\nThe Board of Directors and Management of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Audit Committee of the Board has approved the engagement of UHY LLP (“UHY”) headquartered in the U.S. as its independent auditor and registered public accounting firm, effective today, October 24, 2025. UHY is a U.S. member of Urbach Hacker Young International Limited (UHY International), a UK company, and forms part of the international UHY network of legally independent accounting and consulting firms.\n\n\nAs a matter of priority, UHY will work with SINOVAC’s management team and the Board’s Audit Committee to audit financial statements for the years ended December 31, 2021, 2022, 2023, 2024 and 2025 (including audits of internal control over financial reporting as of December 31, 2024 and 2025), and interim reviews for the six-month periods ended June 30, 2024 and 2025. The Company plans to file Form 20Fs and Form 6-Ks as soon as practicable in order to meet SEC and NASDAQ compliance requirements.\n\n\n“We are pleased to welcome UHY as SINOVAC’s new independent auditor,” said Sven H. Borho, Audit Committee Chair of SINOVAC’s Board. “UHY is a highly respected accounting firm with the global reach and expertise required to work with a business like SINOVAC. Their appointment marks an important step in our ongoing commitment to robust financial oversight and transparency, as we continue to work with NASDAQ toward the aim of the trading resumption.”\n\n\nAbout SINOVAC\n\n\nSinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.\n\n\nSINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc.\n\n\nThe COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under \"Category 1 Pre...